Dr. Matthew Finn, MD
Claim this profileClinical Trials Matthew Finn, MD is currently running
More about Matthew Finn, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Matthew Finn, MD has experience with
- Golazo® Peripheral Atherectomy System
Breakdown of trials Matthew Finn, MD has run
Peripheral Artery Disease
Peripheral Arterial Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Finn, MD specialize in?
Matthew Finn, MD focuses on Peripheral Artery Disease and Peripheral Arterial Disease. In particular, much of their work with Peripheral Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Matthew Finn, MD currently recruiting for clinical trials?
Yes, Matthew Finn, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Matthew Finn, MD has studied deeply?
Yes, Matthew Finn, MD has studied treatments such as Golazo® Peripheral Atherectomy System.
What is the best way to schedule an appointment with Matthew Finn, MD?
Apply for one of the trials that Matthew Finn, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.